Else Nutrition

BioTech Stocks

Company
Last Trade
Change
Volume
Shares Out
Market Cap
NASDAQ REGN REGENERON PHARMACEUTICALS
US$ 701.85
-6.40 -0.90
1.58M
108.07M
US$ 75.850B
Follow
NASDAQ BNTX BIONTECH
US$ 113.08
1.74 1.56
812,484
239.74M
US$ 27.110B
Follow
NASDAQ MRNA MODERNA
US$ 39.39
-0.17 -0.43
23.80M
384.82M
US$ 15.160B
Follow
NASDAQ ROIV ROIVANT SCIENCES
US$ 11.57
0.07 0.61
11.98M
727.95M
US$ 8.420B
Follow
NASDAQ NUVL NUVALENT
US$ 84.22
-0.42 -0.50
1.19M
65.62M
US$ 5.530B
Follow
NASDAQ BBIO BRIDGEBIO PHARMA
US$ 26.49
0.28 1.07
3.61M
188.99M
US$ 5.010B
Follow
NASDAQ KRYS KRYSTAL BIOTECH
US$ 164.83
4.00 2.49
665,329
28.76M
US$ 4.740B
Follow
NASDAQ ACLX ARCELLX
US$ 75.54
0.33 0.44
1.21M
54.07M
US$ 4.080B
Follow
NASDAQ EWTX EDGEWISE THERAPEUTICS
US$ 30.78
-0.02 -0.06
1.04M
94.69M
US$ 2.910B
Follow
NASDAQ MRUS MERUS
US$ 41.85
-0.24 -0.57
723,833
68.46M
US$ 2.870B
Follow
NASDAQ VERA VERA THERAPEUTICS
US$ 42.60
0.55 1.31
2.18M
63.32M
US$ 2.700B
Follow
NASDAQ KYMR KYMERA THERAPEUTICS
US$ 40.66
1.52 3.88
958,114
64.77M
US$ 2.630B
Follow
NASDAQ RXRX RECURSION PHARMACEUTICALS
US$ 6.08
-0.01 -0.16
19.19M
381.90M
US$ 2.320B
Follow
NASDAQ CNTA CENTESSA PHARMACEUTICALS
US$ 17.16
-0.39 -2.22
780,241
131.84M
US$ 2.260B
Follow
NASDAQ LBPH LONGBOARD PHARMACEUTICALS
US$ 60.00
0.00 0.00
0
34.29M
US$ 2.060B
Follow
NASDAQ BLTE BELITE BIO
US$ 64.12
0.68 1.07
57,193
30.88M
US$ 1.980B
Follow
NASDAQ CERT CERTARA
US$ 11.59
0.00 0.00
0
160.98M
US$ 1.870B
Follow
NASDAQ EQRX EQRX
US$ 2.34
0.00 0.00
0
487.70M
US$ 1.140B
Follow
NYSE NUVB NUVATION BIO
US$ 2.68
-0.01 -0.37
2.63M
335.57M
US$ 899.330M
Follow
NASDAQ ABCL ABCELLERA BIOLOGICS
US$ 2.91
0.00 0.00
0
295.37M
US$ 859.530M
Follow
NASDAQ ICVX ICOSAVAX
US$ 15.31
0.00 0.00
0
50.23M
US$ 769.020M
Follow
NASDAQ AVXL ANAVEX LIFE SCIENCES
US$ 8.63
0.16 1.89
2.37M
84.80M
US$ 731.820M
Follow
NASDAQ BCYC BICYCLE THERAPEUTICS
US$ 14.68
-0.32 -2.13
343,475
47.55M
US$ 698.030M
Follow
NASDAQ HUMA HUMACYTE
US$ 4.60
1.14 32.95
74.90M
128.67M
US$ 591.880M
Follow
OTCMKTS ELTP ELITE PHARMACEUTICALS
US$ 0.55
-0.02 -3.51
331,169
1.07B
US$ 588.500M
Follow
NASDAQ TERN TERNS PHARMACEUTICALS
US$ 5.86
-0.19 -3.14
3.96M
84.94M
US$ 497.750M
Follow
NYSE DNA GINKGO BIOWORKS
US$ 10.08
1.34 15.33
1.57M
45.20M
US$ 455.620M
Follow
NASDAQ ESPR ESPERION THERAPEUTICS
US$ 2.19
0.02 0.69
5.92M
197.04M
US$ 431.520M
Follow
NASDAQ CDXC CHROMADEX
US$ 5.49
0.08 1.48
1.13M
76.38M
US$ 419.330M
Follow
NASDAQ SANA SANA BIOTECHNOLOGY
US$ 1.65
0.05 3.12
3.19M
223.27M
US$ 368.400M
Follow
NASDAQ DSGN DESIGN THERAPEUTICS
US$ 6.25
0.26 4.34
536,586
56.62M
US$ 353.880M
Follow
NASDAQ ABSI ABSCI
US$ 2.99
0.07 2.40
2.40M
114.86M
US$ 343.430M
Follow
OTCMKTS NWBO NORTHWEST BIOTHERAPEUTICS
US$ 0.26
0.0037 1.44
1.65M
1.30B
US$ 338.000M
Follow
NASDAQ CMPS COMPASS PATHWAYS
US$ 4.20
0.00 0.00
0
68.42M
US$ 287.500M
Follow
NASDAQ AMLX AMYLYX PHARMACEUTICALS
US$ 4.05
0.09 2.27
517,781
68.55M
US$ 277.630M
Follow
NASDAQ LXRX LEXICON PHARMACEUTICALS
US$ 0.72
-0.0086 -1.19
6.57M
361.49M
US$ 258.470M
Follow
NASDAQ ACRS ACLARIS THERAPEUTICS
US$ 2.72
-0.05 -1.81
1.15M
71.43M
US$ 194.290M
Follow
NASDAQ PROK PROKIDNEY
US$ 1.51
0.05 3.42
1.22M
127.97M
US$ 193.230M
Follow
NASDAQ GRPH GRAPHITE BIO
US$ 3.18
0.00 0.00
0
58.24M
US$ 185.200M
Follow
NASDAQ NKTX NKARTA
US$ 2.37
0.17 7.73
1.87M
70.57M
US$ 167.250M
Follow
NASDAQ CRBP CORBUS PHARMACEUTICALS
US$ 13.00
-0.33 -2.48
967,414
12.18M
US$ 158.340M
Follow
NASDAQ BMEA BIOMEA FUSION
US$ 4.23
0.15 3.68
831,926
36.24M
US$ 153.300M
Follow
OTCMKTS NGENF NERVGEN PHARMA
US$ 2.07
-0.09 -4.17
23,485
70.31M
US$ 145.540M
Follow
NASDAQ TNYA TENAYA THERAPEUTICS
US$ 1.70
0.29 20.57
9.26M
79.22M
US$ 134.670M
Follow
NASDAQ DBTX DECIBEL THERAPEUTICS
US$ 4.91
0.00 0.00
0
25.13M
US$ 123.390M
Follow
NASDAQ PEPG PEPGEN
US$ 3.63
-0.46 -11.25
850,021
32.60M
US$ 118.340M
Follow
NYSEAMEX ZOM ZOMEDICA
US$ 0.12
0.00 0.00
9.25M
979.95M
US$ 117.590M
Follow
NASDAQ TALS TALARIS THERAPEUTICS
US$ 2.72
0.00 0.00
0
42.81M
US$ 116.440M
Follow
NASDAQ TNXP TONIX PHARMACEUTICALS
US$ 0.61
0.04 7.54
263.23M
186.89M
US$ 114.560M
Follow
NASDAQ SAVA CASSAVA SCIENCES
US$ 2.35
0.06 2.62
3.16M
48.11M
US$ 113.060M
Follow
NASDAQ CRDL CARDIOL THERAPEUTICS
US$ 1.29
-0.03 -1.91
411,654
81.60M
US$ 104.860M
Follow
NASDAQ HLVX HILLEVAX
US$ 1.86
0.03 1.64
696,194
49.81M
US$ 92.650M
Follow
NASDAQ NVCT NUVECTIS PHARMA
US$ 4.53
-0.16 -3.41
138,902
19.32M
US$ 87.520M
Follow
NASDAQ ADAG ADAGENE
US$ 1.95
-0.06 -2.99
36,353
44.27M
US$ 86.330M
Follow
NASDAQ AADI AADI BIOSCIENCE
US$ 3.35
1.01 43.16
8.82M
24.65M
US$ 82.580M
Follow
OTCMKTS SKYE SKYE BIOSCIENCE
US$ 2.70
-0.16 -5.59
436,517
30.34M
US$ 81.920M
Follow
NASDAQ QNCX QUINCE THERAPEUTICS
US$ 1.78
0.02 1.14
101,734
44.00M
US$ 78.320M
Follow
NASDAQ IKNA IKENA ONCOLOGY
US$ 1.55
-0.06 -3.73
174,967
48.26M
US$ 74.800M
Follow
NASDAQ LABP LANDOS BIOPHARMA
US$ 22.93
0.00 0.00
0
3.13M
US$ 71.770M
Follow
NASDAQ GALT GALECTIN THERAPEUTICS
US$ 1.04
-0.96 -48.00
9.17M
62.76M
US$ 65.270M
Follow
NASDAQ RGC REGENCELL BIOSCIENCE
US$ 4.92
-0.31 -5.93
2,407
13.01M
US$ 64.010M
Follow
NASDAQ IMRX IMMUNEERING
US$ 2.01
0.17 9.24
681,067
31.05M
US$ 62.410M
Follow
NYSE ANVS ANNOVIS BIO
US$ 4.37
-0.03 -0.68
315,412
13.80M
US$ 60.310M
Follow
NASDAQ VOR VOR BIOPHARMA
US$ 0.87
-0.02 -1.77
217,886
68.67M
US$ 59.810M
Follow
NASDAQ IMMX IMMIX BIOPHARMA
US$ 2.16
-0.06 -2.70
81,789
27.51M
US$ 59.420M
Follow
NASDAQ IVVD INVIVYD
US$ 0.44
0.01 3.33
2.11M
119.62M
US$ 53.110M
Follow
NASDAQ DYAI DYADIC INTERNATIONAL
US$ 1.75
-0.16 -8.14
265,579
29.59M
US$ 51.780M
Follow
NASDAQ OMIC SINGULAR GENOMICS SYSTEMS
US$ 19.55
-0.39 -1.96
17,450
2.51M
US$ 49.070M
Follow
NASDAQ AGLE AEGLEA BIOTHERAPEUTICS
US$ 12.01
0.00 0.00
0
4.05M
US$ 48.640M
Follow
NASDAQ RANI RANI THERAPEUTICS
US$ 1.41
0.11 8.46
449,167
33.31M
US$ 46.970M
Follow
OTCMKTS MEDXF MEDEXUS PHARMACEUTICALS
US$ 1.88
-0.03 -1.57
99
24.65M
US$ 46.340M
Follow
NASDAQ OMGA OMEGA THERAPEUTICS
US$ 0.83
0.02 2.04
176,647
55.37M
US$ 45.900M
Follow
NASDAQ GANX GAIN THERAPEUTICS
US$ 1.57
-0.005 -0.32
149,458
26.53M
US$ 41.520M
Follow
NASDAQ VTVT VTV THERAPEUTICS
US$ 15.80
0.00 0.00
0
2.61M
US$ 41.240M
Follow
NASDAQ RLYB RALLYBIO
US$ 0.95
-0.03 -2.58
97,054
41.49M
US$ 39.460M
Follow
NASDAQ CDIO CARDIO DIAGNOSTICS
US$ 0.97
-0.05 -4.51
3.61M
40.44M
US$ 39.390M
Follow
NASDAQ LEXX LEXARIA BIOSCIENCE
US$ 2.20
-0.01 -0.45
68,667
17.45M
US$ 38.390M
Follow
NASDAQ RAIN RAIN ONCOLOGY
US$ 1.21
0.00 0.00
0
27.58M
US$ 33.370M
Follow
NASDAQ CMMB CHEMOMAB THERAPEUTICS
US$ 1.66
0.04 2.47
42,204
18.86M
US$ 31.310M
Follow
NASDAQ ANGN ANGION BIOMEDICA
US$ 1.00
0.00 0.00
0
30.11M
US$ 30.110M
Follow
NASDAQ PMN PROMIS NEUROSCIENCES
US$ 0.92
0.02 1.88
45,605
32.69M
US$ 30.070M
Follow
NASDAQ RNXT RENOVORX
US$ 1.25
0.10 8.70
95,383
24.00M
US$ 30.000M
Follow
NASDAQ IXHL INCANNEX HEALTHCARE
US$ 1.70
-0.09 -4.76
20,333
17.64M
US$ 29.990M
Follow
NASDAQ LVTX LAVA THERAPEUTICS
US$ 1.03
0.04 4.16
163,921
26.30M
US$ 27.090M
Follow
NASDAQ PLUR PLUR
US$ 4.82
0.42 9.55
13,334
5.56M
US$ 26.800M
Follow
NASDAQ ANEB ANEBULO PHARMACEUTICALS
US$ 1.00
-0.11 -9.91
85,510
25.93M
US$ 25.930M
Follow
NASDAQ BNGO BIONANO GENOMICS
US$ 0.24
0.00 0.00
0
101.99M
US$ 24.070M
Follow
NASDAQ LSTA LISATA THERAPEUTICS
US$ 2.66
0.14 5.56
18,557
8.39M
US$ 22.320M
Follow
NASDAQ LGVN LONGEVERON
US$ 1.65
0.05 3.12
313,593
13.35M
US$ 22.030M
Follow
OTCMKTS DTCFF DEFENCE THERAPEUTICS
US$ 0.46
0.00 0.00
0
47.09M
US$ 21.630M
Follow
NASDAQ BCTX BRIACELL THERAPEUTICS
US$ 0.57
-0.02 -2.58
909,956
36.31M
US$ 20.700M
Follow
NASDAQ SEEL SEELOS THERAPEUTICS
US$ 2.91
0.00 0.00
0
6.98M
US$ 20.310M
Follow
NASDAQ HOOK HOOKIPA PHARMA
US$ 2.00
-0.14 -6.54
68,926
9.66M
US$ 19.320M
Follow
NASDAQ BOLT BOLT BIOTHERAPEUTICS
US$ 0.50
-0.06 -10.73
70,138
38.27M
US$ 19.100M
Follow
NASDAQ AMRS AMYRIS
US$ 0.05
0.00 0.00
0
369.39M
US$ 18.470M
Follow
NASDAQ SNTI SENTI BIOSCIENCES
US$ 3.97
-0.01 -0.25
190,657
4.59M
US$ 18.220M
Follow
NASDAQ INAB IN8BIO
US$ 0.25
0.0086 3.58
1.32M
72.48M
US$ 18.050M
Follow
NASDAQ FNCH FINCH THERAPEUTICS
US$ 10.35
0.00 0.00
0
1.61M
US$ 16.660M
Follow
NASDAQ BIAF BIOAFFINITY TECHNOLOGIES
US$ 1.02
-0.16 -13.56
493,480
15.58M
US$ 15.890M
Follow
NYSEAMEX NHWK NIGHTHAWK BIOSCIENCES
US$ 0.41
0.00 0.00
0
36.03M
US$ 14.900M
Follow
NASDAQ ERNA ETERNA THERAPEUTICS
US$ 0.25
0.0025 1.01
572,018
51.37M
US$ 12.840M
Follow
OTCMKTS OTLC ONCOTELIC THERAPEUTICS
US$ 0.03
0.003 10.71
32,416
407.29M
US$ 12.630M
Follow
NASDAQ IPA IMMUNOPRECISE ANTIBODIES
US$ 0.40
-0.02 -4.78
199,627
31.06M
US$ 12.420M
Follow
NASDAQ IMNN IMUNON
US$ 0.83
-0.02 -2.83
1.01M
14.50M
US$ 12.040M
Follow
NASDAQ KTRA KINTARA THERAPEUTICS
US$ 0.22
0.00 0.00
0
55.66M
US$ 11.990M
Follow
OTCMKTS VPHIF VALEO PHARMA
US$ 0.12
0.00 0.00
0
98.66M
US$ 11.650M
Follow
NASDAQ SNSE SENSEI BIOTHERAPEUTICS
US$ 0.45
0.02 4.65
284,257
25.15M
US$ 11.320M
Follow
NASDAQ MDNA MEDICENNA THERAPEUTICS
US$ 0.16
0.00 0.00
0
69.64M
US$ 10.930M
Follow
NASDAQ ENSC ENSYSCE BIOSCIENCES
US$ 8.10
0.15 1.89
150,348
1.30M
US$ 10.530M
Follow
OTCMKTS NBIO NASCENT BIOTECH
US$ 0.06
0.00 0.00
0
172.20M
US$ 10.330M
Follow
NASDAQ KPRX KIORA PHARMACEUTICALS
US$ 3.28
0.04 1.23
23,441
3.00M
US$ 9.840M
Follow
NASDAQ ICU SEASTAR MEDICAL
US$ 2.03
-0.009 -0.44
201,282
4.46M
US$ 9.060M
Follow
OTCMKTS TBRIF THERMA BRIGHT
US$ 0.02
0.00 0.00
0
443.14M
US$ 8.860M
Follow
NASDAQ RDHL REDHILL BIOPHARMA
US$ 6.69
0.22 3.40
12,616
1.28M
US$ 8.560M
Follow
NASDAQ AYTU AYTU BIOSCIENCE
US$ 1.38
0.00 0.00
25,449
6.15M
US$ 8.490M
Follow
NASDAQ MBIO MUSTANG BIO
US$ 0.17
0.0089 5.39
890,589
48.77M
US$ 8.490M
Follow
OTCMKTS HYEX HEALTHY EXTRACTS
US$ 2.60
0.00 0.00
0
2.99M
US$ 7.770M
Follow
NASDAQ VRAX VIRAX BIOLABS
US$ 1.75
-0.14 -7.41
383,935
4.34M
US$ 7.600M
Follow
NASDAQ PRTG PORTAGE BIOTECH
US$ 6.00
0.15 2.56
56,392
1.12M
US$ 6.720M
Follow
NASDAQ XBIO XENETIC BIOSCIENCES
US$ 4.16
-0.12 -2.80
3,142
1.54M
US$ 6.410M
Follow
OTCMKTS VYYRF VOYAGEUR PHARMACEUTICALS
US$ 0.05
0.00 0.00
0
139.47M
US$ 6.280M
Follow
NASDAQ GLTO GALECTO
US$ 4.72
0.06 1.29
15,344
1.32M
US$ 6.230M
Follow
NASDAQ RPHM RENEO PHARMACEUTICALS
US$ 1.82
0.00 0.00
0
3.34M
US$ 6.080M
Follow
OTCMKTS TDSGF TELO GENOMICS
US$ 0.08
0.00 0.00
6,000
74.56M
US$ 5.960M
Follow
NASDAQ COEP COEPTIS THERAPEUTICS
US$ 0.14
-0.0015 -1.04
365,280
41.12M
US$ 5.880M
Follow
NASDAQ IMPL IMPEL PHARMACEUTICALS
US$ 0.24
0.00 0.00
0
23.90M
US$ 5.760M
Follow
NASDAQ SBFM SUNSHINE BIOPHARMA
US$ 2.78
-0.02 -0.71
111,772
2.00M
US$ 5.560M
Follow
OTCMKTS BICX BIOCOR RX
US$ 0.43
0.00 0.00
0
12.75M
US$ 5.480M
Follow
OTCMKTS TRYPF TRYP THERAPEUTICS
US$ 0.06
0.00 0.00
0
96.42M
US$ 5.420M
Follow
NASDAQ EDSA EDESA BIOTECH
US$ 1.65
-0.10 -5.71
22,954
3.25M
US$ 5.360M
Follow
NASDAQ CMND CLEARMIND MEDICINE
US$ 1.21
0.02 1.68
41,172
4.38M
US$ 5.300M
Follow
OTCMKTS SIGY SIGYN THERAPEUTICS
US$ 3.25
0.00 0.00
0
1.61M
US$ 5.230M
Follow
NASDAQ CHEK CHECK-CAP
US$ 0.81
0.00 0.00
0
5.85M
US$ 4.740M
Follow
NASDAQ FRTX FRESH TRACKS THERAPEUTICS
US$ 0.74
-0.05 -5.95
19
5.97M
US$ 4.440M
Follow
NASDAQ VIRI VIRIOS THERAPEUTICS
US$ 0.16
0.00 0.00
0
27.76M
US$ 4.300M
Follow
NASDAQ HGEN HUMANIGEN
US$ 0.04
0.00 0.00
0
119.08M
US$ 4.300M
Follow
OTCMKTS CELZ CREATIVE MEDICAL TECHNOLOGY HOLDINGS
US$ 2.08
0.08 4.00
19,029
1.75M
US$ 3.640M
Follow
NASDAQ XRTX XORTX THERAPEUTICS
US$ 1.10
-0.02 -1.79
11,452
3.22M
US$ 3.540M
Follow
NASDAQ KTTA PASITHEA THERAPEUTICS
US$ 2.76
0.09 3.52
21,489
1.27M
US$ 3.510M
Follow
OTCMKTS LOBEF LOBE SCIENCES
US$ 0.02
0.0087 84.47
5,000
171.56M
US$ 3.260M
Follow
NYSEAMEX TOVX THERIVA BIOLOGICS
US$ 1.15
0.00 0.00
37,105
2.78M
US$ 3.200M
Follow
OTCMKTS AVRW AVENIR WELLNESS
US$ 0.04
0.00 0.00
0
78.93M
US$ 3.160M
Follow
OTCMKTS APLIF APPILI THERAPEUTICS
US$ 0.03
0.00 0.00
0
121.27M
US$ 3.030M
Follow
OTCMKTS ODYY ODYSSEY GROUP
US$ 0.03
0.00 0.00
0
96.71M
US$ 2.900M
Follow
NASDAQ RNAZ TRANSCODE THERAPEUTICS
US$ 3.76
-0.09 -2.34
71,659
696,249
US$ 2.620M
Follow
OTCMKTS RVVTF REVIVE THERAPEUTICS
US$ 0.006
-0.0002 -3.23
738,900
418.56M
US$ 2.510M
Follow
NASDAQ PALI PALISADE BIO
US$ 1.75
-0.05 -2.78
112,837
1.43M
US$ 2.500M
Follow
NASDAQ CFRX CONTRAFECT
US$ 0.23
0.00 0.00
0
10.70M
US$ 2.480M
Follow
NASDAQ BPTS BIOPHYTIS
US$ 8.22
0.00 0.00
0
286,504
US$ 2.360M
Follow
NASDAQ SHPH SHUTTLE PHARMACEUTICALS
US$ 0.64
-0.04 -5.88
124,547
3.66M
US$ 2.340M
Follow
OTCMKTS ACOGF ALPHA COGNITION
US$ 0.38
0.00 0.00
0
6.03M
US$ 2.290M
Follow
NASDAQ BIOR BIORA THERAPEUTICS
US$ 0.49
-0.07 -13.17
54,996
4.52M
US$ 2.200M
Follow
OTCMKTS SZLSF STAGEZERO LIFE SCIENCES
US$ 0.01
0.00 0.00
0
123.53M
US$ 1.610M
Follow
OTCMKTS MYNDF MYND LIFE SCIENCES
US$ 0.03
0.00 0.00
0
47.82M
US$ 1.430M
Follow
OTCMKTS AGNPF ALGERNON PHARMACEUTICALS
US$ 0.04
-0.003 -7.32
344
27.30M
US$ 1.040M
Follow
NASDAQ UPC UNIVERSE PHARMACEUTICALS
US$ 0.64
0.002 0.31
237,070
1.58M
US$ 1.010M
Follow
OTCMKTS AQSZF AEQUUS PHARMACEUTICALS
US$ 0.007
0.00 0.00
0
132.63M
US$ 928K
Follow
NASDAQ PXMD PAXMEDICA
US$ 0.07
-0.62 -89.39
652
10.88M
US$ 794K
Follow
OTCMKTS PRXTF PURE EXTRACTS
US$ 0.0054
0.00 0.00
0
116.77M
US$ 631K
Follow
OTCMKTS NMLSF NOVA MENTIS LIFE SCIENCES
US$ 0.02
0.00 0.00
0
36.02M
US$ 540K
Follow
NASDAQ NEXI NEXIMMUNE
US$ 0.27
0.00 0.00
0
1.39M
US$ 377K
Follow
OTCMKTS TRMNF NEW WAVE HOLDINGS
US$ 0.008
0.00 0.00
0
35.87M
US$ 287K
Follow
NASDAQ HUGE FSD PHARMA
US$ 0.09
0.00 0.00
0
708,609
US$ 64K
Follow
NASDAQ EVLO EVELO BIOSCIENCES
US$ 0.001
0.00 0.00
0
18.98M
US$ 19K
Follow
OTCMKTS BIOAF BIOASIS TECHNOLOGIES
US$ 0.0001
0.00 0.00
0
79.41M
US$ 8K
Follow
NASDAQ CMRA COMERA LIFE SCIENCES
US$ 0.0001
0.00 0.00
0
30.74M
US$ 3K
Follow
OTCMKTS GDBYF GOODBODY HEALTH
US$ 0.00
0.00 0.00
0
36.50M
US$ -
Follow
NASDAQ ALTS ALT5 SIGMA
US$ 2.56
0.00 0.00
0
-
US$ -
Follow
NASDAQ EFTR EFFECTOR THERAPEUTICS
US$ 0.00
-0.18 -100.00
280
4.70M
US$ -
Follow

BioTech News

Green Stock News

Lexicon Pharmaceuticals Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin)

December 20, 2024

    THE WOODLANDS, Texas, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced it has received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for Zynquista™ (sotagliflozin) as an adjunct to insulin therapy for glycemic control in adults with type 1 diabetes and chronic kidney disease... Read more

    Green Stock News

    Galectin Therapeutics Announces Top-Line Results of NAVIGATE Clinical Trial Evaluating Belapectin in Patients with Cirrhotic Portal Hypertension Caused by MASH

    December 20, 2024

      In the pre-specified per-protocol population, belapectin showed a statistically significant reduction (p-value < 0.05) in development of esophageal varices in 2mg/kg cohort compared to placebo While there was a favorable trend for incidence of varices in the primary end point intent-to-treat population, belapectin did not achieve statistical significance Belapectin was overall well tolerated... Read more

      Green Stock News

      Voyageur Pharmaceuticals Signs Letter of Intent with Global Contrast Imaging Company to Expand Market Reach and Product Portfolio

      December 20, 2024

        LOI Agreement is steppingstone to formal agreement,   The Multinational Pharmaceutical company is ranked in the top five contrast agent suppliers in the world, signaling and solidifying Voyageur’s importance in the global contrast agent market  Calgary, Alberta, Canada – TheNewswire - December 20, 2024 - Voyageur Pharmaceuticals Ltd. (TSXV:VM) (OTC Pink:VYYRF) ("Voyageur"... Read more

        Green Stock News

        Humacyte Announces FDA Approval of SYMVESS™ (acellular tissue engineered vessel-tyod) for the Treatment of Extremity Vascular Trauma

        December 19, 2024

          SYMVESS is a first-in-class bioengineered human tissue designed to be a universally implantable vascular conduit for use in arterial replacement and repair  In clinical testing SYMVESS was observed to have high rates of patency, or blood flow, and low rates of amputation and infection  Highly experienced sales team already recruited and trained in preparation for commercial launch&... Read more

          Green Stock News

          Regeneron Pharmaceuticals to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept Results

          December 19, 2024

            Investigational REGN7508 (catalytic domain) and REGN9933 (A2 domain) are being evaluated for their potential to control thrombosis while minimizing bleeding risk in a variety of patient populations and clinical settings Evaluated against current standards of care, single doses of REGN7508 and REGN9933 administered 12 to 24 hours after total knee replacement demonstrated robust antithrombotic effects... Read more

            Green Stock News

            Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis

            December 19, 2024

              All four patients treated with NXC-201 normalized their disease markers within 30 days of dosing, of which, two are already classified as complete responders (CR), and the remaining two are bone marrow MRD negative (10-6); all patients remain in response as of the data cutoff of Nov 14, 2024 Bone marrow MRD negativity predicts future CR; company believes remaining two patients could be confirmed... Read more

              Green Stock News

              Aadi Bioscience Transforms with In-Licensing of Novel ADC Portfolio, $100 Million Sale of FYARRO® and $100 Million PIPE Financing

              December 19, 2024

                Aadi Enters into Exclusive License for Three-Asset ADC Portfolio Developed through a Collaboration between WuXi Biologics and HANGZHOU DAC Aadi Enters Agreement to Sell FYARRO® and Associated Infrastructure to KAKEN Pharmaceutical for $100M; Announces PIPE Financing of $100M Cumulative Capital Expected to Fund Operations into Late 2028, Including Anticipated Clinical Data for the ADC P... Read more

                Green Stock News

                Lexaria Bioscience Registered GLP-1 Study #4 Begins Dosing

                December 19, 2024

                  Registered Phase-1b 12-week study will investigate safety, diabetes control, and weight loss KELOWNA, BC / ACCESSWIRE / December 19, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces it has begun dosing in the Company's Phase 1b, 12-week chronic study GLP-1-H24-4, (the "Study"). The Study is designed... Read more

                  Green Stock News

                  IMUNON Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer

                  December 19, 2024

                    Company aligned with FDA on CMC strategy and requirements in preparation of Phase 3 pivotal trial of IMNN-001 Vertical integration of major components assures a high-quality, commercially viable future manufacturing capability On track to initiate Phase 3 pivotal trial of IMNN-001 in first quarter of 2025 LAWRENCEVILLE, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a... Read more

                    Green Stock News

                    Shuttle Pharmaceuticals Enters into Sponsored Research Agreement with the University of California, San Francisco to Advance PSMA Development Program

                    December 19, 2024

                      GAITHERSBURG, Md., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced a sponsored research agreement with the University of California, San Francisco (UCSF) to advance... Read more

                      Green Stock News

                      Immuneering Launches Pancreatic Cancer Advisory Board

                      December 19, 2024

                        Establishment reflects the clinical progress of IMM-1-104 and its promise in pancreatic cancer  Follows recent Orphan Drug designation in pancreatic cancer and Fast Track designations in first- and second-line pancreatic cancer for IMM-1-104  CAMBRIDGE, Mass., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop... Read more

                        Green Stock News

                        Krystal Biotech Announces Early Evidence of Monotherapy Activity in Heavily Pre-Treated Patients with Advanced Non-Small Cell Lung Cancer

                        December 18, 2024

                          Preliminary clinical data in post-anti-PD-1 NSCLC patients demonstrated a 27% ORR and 73% DCR in monotherapy trial Monotherapy activity with inhaled KB707 provides further evidence of successful repeat administration of HSV-1 based inhaled lung gene delivery and builds on recent clinical data update for CF and AAT deficiency respiratory disease programs PITTSBURGH, Dec. 18, 2024 (GLOBE NEWSWIRE)... Read more

                          Green Stock News

                          TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial

                          December 18, 2024

                            Approval given after Safety Review Committee (SRC) review of safety data from the three patients comprising Cohort 2 No significant safety or dose limiting toxicities reported in Cohort 2 New patients currently being evaluated for eligibility in Cohort 3 PK and PD data from Cohort 1 patients consistent with preclinical and Phase 0 trial results BOSTON, Dec. 18, 2024 /PRNewswire/ -- TransCode... Read more

                            Green Stock News

                            Therma Bright Signs LOI For U.S. Distribution Network Expansion For Venowave With DME Authority

                            December 18, 2024

                              Initiative Includes Milestone-Based Inventory Purchase Commitments During Q1 and Q2, 2025 Toronto, Ontario--(Newsfile Corp. - December 18, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX) ("Therma" or the "Company"), a developer and investment partner specializing in advanced diagnostic and medical device technologies, is pleased to announce the Company has signed a letter of... Read more

                              Green Stock News

                              Lexaria Bioscience Forms New Scientific Advisory Board

                              December 18, 2024

                                North American drug delivery development experts added to help guide Lexaria's strategic plans KELOWNA, BC / ACCESSWIRE / December 18, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces the creation of its new Scientific Advisory Board ("SAB") to assist in guiding Lexaria's rapid drug delivery platform... Read more

                                Green Stock News

                                Regeneron Pharmaceuticals: EYLEA HD® (aflibercept) Injection 8 mg Phase 3 Trial Meets Primary Endpoint Showing Improved Vision with Extended Dosing Intervals in Patients with Macular Edema following Retinal...

                                December 17, 2024

                                  EYLEA HD demonstrated non-inferior vision gains with an every 8-week dosing regimen compared to EYLEA® (aflibercept) Injection 2 mg dosed every 4 weeks Safety data remains consistent with the known EYLEA HD and EYLEA safety profiles Supplementary biologics license application planned for submission to the U.S. Food and Drug Administration in the first quarter of 2025 TARRYTOWN, N.Y., Dec.... Read more

                                  Green Stock News

                                  Tonix Pharmaceuticals Announces FDA Acceptance of the New Drug Application (NDA) for TNX-102 SL for Fibromyalgia

                                  December 17, 2024

                                    FDA is expected to assign a Prescription Drug User Fee Act (PDUFA) target action date and announce whether Priority Review has been granted in the Day 74 Letter TNX-102 SL is a non-opioid, centrally acting analgesic, granted Fast Track designation by FDA Fibromyalgia affects more than 10 million adults in the U.S. who are mostly women TNX-102 SL has the potential to be the first member of a... Read more

                                    Green Stock News

                                    Ginkgo Bioworks Awarded $9.4 Million in Partnership with Carnegie Mellon University to Develop Implantable Cell-Based Bioelectronic Devices for Disease Treatment Under ARPA-H's REACT Program

                                    December 17, 2024

                                      Ginkgo Bioworks to apply its mammalian cell engineering expertise to develop new cell-based systems for treating and monitoring endocrine disorders BOSTON, Dec. 17, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a subcontract of up to $9.4 million awarded in partnership with Carnegie Mellon University... Read more

                                      Green Stock News

                                      Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes

                                      December 17, 2024

                                        Icovamenib met the primary endpoint, displaying a meaningful statistically significant placebo-corrected mean reduction in HbA1c in the prespecified per protocol patient population Best response achieved in target, beta-cell deficient patients on one or more antidiabetic agents at baseline, showing a placebo-adjusted mean reduction of 1.47% in HbA1c at Week 26 with statistical significance, after... Read more

                                        Green Stock News

                                        Tenaya Therapeutics Reports Promising Early Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy

                                        December 17, 2024

                                          TN-201 Well Tolerated at 3E13 vg/kg Dose AAV9 Capsid Demonstrated Robust Delivery of TN-201 Transgene to Heart Muscle Cells Resulting in Increasing RNA Expression and an Increase in Protein Levels Observed at One Year Circulating Biomarkers and Other Clinical Measures Mostly Remained Stable or Improved from Baseline Tenaya Management to Host a Webcast Conference Call Today at 8:00 a.m. ET SOUTH... Read more

                                          Green Stock News

                                          Portage Biotech Announces Letter of Intent with Immunova for an Option to Acquire iOx Therapeutics

                                          December 17, 2024

                                            WESTPORT, Conn., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Portage Biotech, Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of novel multi-targeted therapies for use as monotherapy and in combination, is pleased to announce that it has entered into a Letter of Intent (“LOI”) with Immunova, LLC, (“Immunova”) a private Connecticut-based... Read more

                                            Green Stock News

                                            Esteemed Harvard Medical School Professor Dr. Michael Gibson Appointed Chief Medical Advisor at Lexaria Bioscience

                                            December 17, 2024

                                              Dr. Gibson joining Lexaria's new scientific advisor board KELOWNA, BC / ACCESSWIRE / December 17, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces the appointment of Dr. Michael Gibson as its new Chief Medical Advisor. Dr. Gibson will collaborate directly with President John Docherty as Lexaria's... Read more

                                              Green Stock News

                                              Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board

                                              December 17, 2024

                                                Carlsbad, CA, Dec. 17, 2024 (GLOBE NEWSWIRE) --  Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for patients with autoimmune, inflammatory, and fibrotic diseases, today announced the appointment of Brian G. Feagan, MD, FRCPC, to its Clinical Advisory Board. Dr. Feagan... Read more

                                                Green Stock News

                                                Edgewise Therapeutics Announces Positive Topline Results from the CANYON Phase 2 Trial of Sevasemten in Individuals with Becker Muscular Dystrophy (Becker)

                                                December 16, 2024

                                                  Trial met primary endpoint of reduction in circulating levels of creatine kinase (CK), a biomarker associated with skeletal muscle damage, in the largest Becker interventional trial to date  On the key secondary endpoint, sevasemten-treated patients showed stabilization of North Star Ambulatory Assessment (NSAA) with a trend towards improvement at 12 months compared to placebo  Sevasemten... Read more

                                                  Green Stock News

                                                  Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC

                                                  December 16, 2024

                                                    UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®) for cancer, today announced that the first patient has been dosed in the Company’s phase 2 trial evaluating petosemtamab monotherapy in heavily pretreated (3L+) metastatic... Read more

                                                    Green Stock News

                                                    Senti Biosciences Announces First Patient Dosed in Clinical Trial of SN301A in Hepatocellular Carcinoma in Collaboration with Celest Therapeutics

                                                    December 16, 2024

                                                      Dose-finding clinical trial in China designed to evaluate safety and preliminary anti-tumor activity of SN301A (SENTI-301A manufactured in China) in hepatocellular carcinoma (“HCC”)  SOUTH SAN FRANCISCO, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies... Read more

                                                      Green Stock News

                                                      Immix Biopharma: Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis

                                                      December 16, 2024

                                                        Chimeric antigen receptor T-cell (CAR-T) cell therapy NXC-201 is a novel approach to treat relapsed/refractory AL Amyloidosis NXC-201 demonstrated compelling clinical activity, rapid and deep complete responses in frail and resistant relapsed/refractory AL Amyloidosis patients LOS ANGELES, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”... Read more

                                                        Green Stock News

                                                        PepGen Announces Clinical Hold in the U.S. on IND Application to Initiate CONNECT2-EDO51 Phase 2 Study of PGN-EDO51 for Duchenne Muscular Dystrophy

                                                        December 16, 2024

                                                          Company continues to advance PGN-EDO51 in CONNECT1-EDO51, with the 10 mg/kg cohort now fully enrolled BOSTON / Dec 16, 2024 / Business Wire / PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that the Company... Read more

                                                          Green Stock News

                                                          Forian Partners With Databricks to Expand Access to Advanced Healthcare Analytics

                                                          December 16, 2024

                                                            NEWTOWN, Pa., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Forian Inc. (Nasdaq: FORA), a leading provider of data science driven information and analytics solutions to the life science, healthcare and financial services industries, today announced a partnership with Databricks, the data and AI company, to deliver access to its Chartis™ product, which maps physician and organization affiliations, through Databricks... Read more

                                                            Green Stock News

                                                            Clearmind Medicine and Dr Glitter Pty Sign Term Sheet for Mutual Development of Novel Psychedelic MEAI- Based Alcohol Substitute in ActivCrystal™ Format

                                                            December 16, 2024

                                                              The term sheet is non-binding, subject to the execution of a definitive agreement  Vancouver, Canada, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today... Read more

                                                              COPYRIGHT ©2022 GREEN STOCK NEWS

                                                              Research Tools
                                                              Stock News
                                                              Popular Topics
                                                              Miscellaneous